- Price
- $86.94
- Day
- -0.42%
- Mkt Cap
- $32.81B
- 52W Range
- $54.11 – $87.83
- Volume
- 5.83M
- Beta
- 1.45
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Dexcom (DXCM) delivered strong Q2/26 results with 13.1% revenue growth, 49.7% operating income growth, and raised FY26 guidance. DXCM's growth drivers include G7 system adoption, international expansion, and initiatives like 'Road to 100' targeting broader diabetes coverage. Margin improvements, ongoing share buybacks, and a robust balance sheet support DXCM's growth and capital allocation strategy.
Read full article
GRMN, LTH and DXCM tap the health and fitness boom through premium clubs, connected wearables and glucose sensing as wellness demand grows.
Read full article
From a technical perspective, DexCom (DXCM) is looking like an interesting pick, as it just reached a key level of support. DXCM recently overtook the 20-day moving average, and this suggests a short-term bullish trend.
Read full article
DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Read full article
Revenue: Worldwide revenue of $1.31 billion, up 13% reported and 12% organic year-over-year.US Revenue: $933 million, up 11% year-over-year.International Revenu
Read full article
DXCM's Q2 earnings and revenues beat estimates as global demand, broader access and margin expansion fuel stronger 2026 guidance.
Read full article
SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Second Quarter 2026 Financial Results.
Read full article
DexCom, Inc. (DXCM) Q2 2026 Earnings Call Transcript
Read full article
DexCom NASDAQ: DXCM reported second-quarter 2026 revenue growth of 13% from a year earlier, supported by continued demand for continuous glucose monitoring systems, expanding reimbursement access and share gains across several patient groups and markets.
Read full article
Medical device maker Dexcom raised its full-year revenue forecast and beat quarterly estimates on Thursday, banking on sustained demand for its continuous glucose monitors that track blood sugar levels, sending shares of the company up over 4% in extended trading.
Read full article
DexCom (DXCM) came out with quarterly earnings of $0.7 per share, beating the Zacks Consensus Estimate of $0.61 per share. This compares to earnings of $0.48 per share a year ago.
Read full article
Dimensional Fund Advisors LP boosted its stake in DexCom, Inc. (NASDAQ: DXCM) by 1.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,895,549 shares of the medical device company's stock after purchasing an additional 23,844 shares during the
Read full article